Skip to main content

Advertisement

Table 1 Patient characteristics

From: Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer

Patient, no.Age [years]PSA [μg/L]PSA doubling time [months]Indication
Gleason
Activity [MBq]Activity/weight [MBq/kg]Local PSMA+Nodal PSMA+Distant PSMA+Therapeutic consequence
1761.48 ADT8RT, ADT. Intensification of the ADT?
4 + 4
3634.78Right prostate0SternumRT prostate. No intensification of the ADT
2670.79BCR after prostatectomy
4 + 3
3554.0302 LNs left iliacal0RT LNs
3661.03> 12BCR after prostatectomy and RT
4 + 3
3473.62000Wait and see
4741.14BCR after prostatectomy
3 + 4
3504.7301 LN left iliacal0S-LAD and RT LN
5634.7n.a.BCR after prostatectomy.
4 + 3
3293.78Right prostate00RT prostate fossa
664130.0
ADT
3Prostatectomy, ADT. Planning local intervention?
n.a.
3843.96Right prostate2 LNs pre-sacral
1 LN right iliacal
> 5 osseous lesionsNo cystectomy
75214.9> 12BCR after prostatectomy and RT
3 + 3
3704.30000Wait and see
8730.85BCR after prostatectomy
4 + 3
3714.9503 LNs retroperitoneal0RT LNs
9741.02> 12BCR after prostatectomy
3 + 4
3794.6000Wait and see
10590.51n.a.BCR after prostatectomy
4 + 3
3453.45000RT prostate fossa
  1. ADT androgen deprivation therapy, BCR biochemical recurrence, LAD lymphadenectomy, LN lymph node, n.a. not available, RT radiotherapy, S-LAD salvage lymphadenectomy